ScholarX: PARK, SE HOON

Detailed Information

PARK, SE HOON (박세훈)

Medicine (Medicine)

Research Area

Tel 02-3410-3459
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Gastric cancer:29||Chemotherapy:22||gastric cancer:18||Stomach neoplasms:13||Urothelial carcinoma:12||immunotherapy:10||Docetaxel:9||Colorectal cancer:9||Prognosis:8||Immunotherapy:8||prognosis:7||Oxaliplatin:7||Capecitabine:7||renal cell carcinoma:7||Pazopanib:6||pembrolizumab:6||HER2:6||Renal cell carcinoma:6||S1:5||urothelial carcinoma:5||bladder cancer:5||KRAS:5||Simvastatin:5||Bladder cancer:5||Adjuvant chemotherapy:5||Radiotherapy:5||Clinical trial:5||chemotherapy:5||Cisplatin:5||Stomach neoplasm:4||Urinary bladder neoplasms:4||Irinotecan:4||Cancer:4||PDL1:4||Advanced gastric cancer:4||Biomarker:4||Recurrence:4||Paclitaxel:4||Survival:4||Gemcitabine:4||#8208:3||Trastuzumab:3||Prognostic factor:3||Prognostic model:3||metastatic renal cell carcinoma:3||FOLFOX:3||Avelumab:3||nextgeneration sequencing:3||Adjuvant:3||Prostate cancer:3||Drug therapy:3||biomarker:3||cisplatin:3||Adjuvant therapy:3||Metastasis:3||Pain:3||Regorafenib:3||Pancreatic cancer:3||radiotherapy:3||Immune checkpoint inhibitors:3||Sarcoma:3||Patientreported outcomes:3||Immunohistochemistry:3||Sorafenib:3||Mutation:3||Therapy:3||EGFR:2||olaratumab:2||plain language summary:2||MerTK:2||Colorectal neoplasms:2||chemoradiation:2||Quality of life:2||genomics:2||lenvatinib:2||immune checkpoint inhibitors:2||Hepatocellular carcinoma:2||adjuvant therapy:2||adjuvant chemotherapy:2||lay summary:2||urothelial cancer:2||ERCC1:2||adjuvant:2||Palliative chemotherapy:2||quality of life:2||AZD2014:2||Predictive:2||Intraperitoneal administration:2||Disseminated intravascular coagulation:2||ramucirumab:2||randomized controlled trial:2||Cetuximab:2||realworld data:2||Haptoglobin:2||refractory cancer:2||ctDNA:2||Salvage:2||Endometrium:2||Carcinoma:2||Atezolizumab:2||dexrazoxane:2||NCT05290038:2||safety:2||salvage therapy:2||sarcoma:2||Sarcopenia:2||Enfortumab vedotin:2||Esophageal squamous cell carcinoma:2||Secondline therapy:2||Concurrent chemoradiotherapy:2||Uterus:2||metastasis:2||Pembrolizumab:2||Gastroenteropancreatic neuroendocrine tumor (GEPNET):2||Irinote:2||Cancer immunotherapy:2||stomach neoplasm:2||maintenance treatment:2||sunitinib:2||survival:2||FGFR:2||gastric/gastroesophageal adenocarcinoma:2||Gastrointestinal stromal tumor:2||Molecular subtype:2||Stomach cancer:2||Preoperative chemoradiotherapy:2||Biweekly:2||Phase 3:2||Epidermal growth factor receptor:2||Neoplasms:2||Everolimus:2||MSI:2||avelumab:2||Phase II:2||Maintenance:2||Maintenance treatment:2||Checkpoint inhibitor:2||MMR:2||overall survival:2||body composition:2||osimertinib:2||RAF inhibitor:2||RAD001:2||Doxorubicin:2||cMET:2||Randomized:2||capecitabine:2||Heparin:1||Hepatocyte growth factor:1||Hiccup:1||Histologic transformation:1||Histological type:1||Histology:1||IDO1:1||IMDC poorrisk:1||IMvigor130:1||Ifosfamide:1||Imatinib:1||Immune:1||Immune checkpoint Inhibitor:1||Immune checkpoint inhibitor:1||Immunebased combinations:1||Immunoconjugates:1||Immunohistochemical stain:1||In situ hybridization:1||Indoleamine 2,3deoxygenase 1:1||Induced hyperthermia:1||Induction chemotherapy:1||Infection:1||Initial dose:1||Investigatorinitiated clinical trial:1||Isomerase:1||JAVELIN Bladder 100:1||KRAS mutation:1||Ki67 index:1||LAG3:1||LY2875358:1||Lenvatinib:1||Liposarcoma:1||Liver metastasis:1||Locallyadvanced:1||Lung Neoplasms:1||MALDITOF:1||MAP2K1 mutation:1||MEK:1||MEK inhibitor:1||MET:1||MET amplification:1||MET exon 14 skipping:1||MET kinase inhibitors:1||MET monoclonal antibodies:1||MET protein, human:1||Macrocytosis:1||Male choriocarcinoma:1||Mass spectrometry:1||Maximum tolerated dose:1||Mesenchymalepithelial transtion tyrosine kinase receptor:1||Metachronous:1||Metastatic:1||Metastatic cancer:1||Metastatic renal cell carcinoma:1||Metastatic urothelial carcinoma:1||Metatstatic colorectal cancer:1||Methylprednisolone:1||Microfluidic chip:1||Microsatellite instability:1||Middleupdown:1||Molecular:1||Molecular profiling:1||Molecular screening:1||Monocarboxylate transporter:1||Monoclonal antibody:1||Muscleinvasive:1||Muscleinvasive urothelial bladder cancer:1||Nglycan:1||NCT05287464:1||NGS:1||NONMEM:1||NanoString:1||Nanostring:1||Neoadjuvant:1||Neoadjuvant chemoradiotherapy:1||Neoadjuvant chemotherapy:1||Neoadjuvant therapy:1||Neoplasm staging:1||Nephrology:1||Nephrology General:1||Neuroendocrine:1||Neurotoxicity:1||Next generation sequencing:1||NextGeneration Sequencing:1||Nextgeneration sequencing:1||Nimotuzumab:1||Nivolumab:1||Nomograms:1||Nonclear cell renal cell carcinoma:1||Nonsmall cell lung cancer:1||Nonsmallcell lung carcinoma:1||Nontransitional cell carcinoma:1||Olaratumab:1||Oligorecurrence:1||Opioid combination:1||Opioid rotation:1||Opioids:1||Overall survival:1||Overall survival final analysis:1||PD1:1||PIK3CA amplification/mutation:1||PIK3CA mutation:1||PIK3CAE542K:1||PIN1:1||PRO007:1||PTEN loss:1||Palbociclib:1||Palliative treatment:1||Pathologic complete response:1||Patientderived cell:1||Patientderived cells:1||Patientderived tumor spheroids:1||Patientreported outcome measures:1||Patterns of failure:1||Pemetrexed:1||Peritoneal seeding:1||Pharmacogenomics:1||Pharmacokinetics:1||Phase 1:1||Phase I:1||Phase I study:1||Phase II study:1||Phase III:1||Platinum chemotherapy:1||Platinum ineligible:1||Platinumbased combination chemotherapy:1||Platinum/gemcitabine:1||Pneumonia:1||Pneumonitis:1||Po:1||Post marketing surveillance:1||Postoperative chemoradiotherapy:1||Poziotinib:1||Practice guideline:1||Prediction:1||Predictive marker:1||Predictive model:1||Preoperative:1||Primary choriocarcinoma:1||Prognostic:1||Prognostic factors:1||Prognosticator:1||Programmed cell death 1 ligand 1:1||Programmed death 1:1||Programmed death ligand 1:1||Programmed death ligand 1 expression:1||Programmed deathligand 1:1||Programmed deathligand 1 (PDL1):1||Propensity score:1||Propensity scorematching:1||Prostate neoplasms:1||Pulmonary metastasis:1||R0 resection:1||RAF1 aberration:1||RAS signature:1||RICTOR:1||RNF11:1||RT:1||Radi:1||Ramucirumab:1||Randomised phase 3 study:1||Randomized controlled trial:1||Randomized trial:1||Rapid infusion:1||Realworld study:1||Receptor, Epidermal Growth Factor:1||Rectal cancer:1||Rectal neoplasms:1||Refractory gastric cancer:1||Renal Cell:1||Renal insufficiency:1||Retrospective:1||Risk factor:1||SAIT301:1||SCLC:1||Salvage therapy:1||Salvage treatment:1||Second line chemotherapy:1||Secondline:1||Sidedness:1||Singlecell RNA sequencing:1||Small cell lung cancer (SCLC):1||Soft tissue sarcoma:1||Solid tumors:1||Sponsorinitiated clinical trial:1||Squamous cell:1||Stomach:1||Sunitinib, dose, toxicity, response:1||Survey:1||Synthetic 3hydroxy3methyglutaryl coenzyme A (HMGCoA):1||TMB:1||TPK1:1||Tanibirumab:1||Target:1||Targeted therapy:1||The effect of bevacizumab was not different between LC and RC and between MSS and the MSIH tumors:1||Thymic carcinoma:1||Thymic epithelial tumors:1||Thymoma:1||Toxicity:1||Transdermal patch:1||Treatment outcome:1||Treatment resistance:1||Treatments in Oncology:1||TruSight™ Oncology 500 assay:1||Tumor microenvironment:1||Tumoral heterogeneity:1||Tyrosine kinase inhibitor:1||Tyrosine kinase inhibitor (TKI):1||Upper tract urothelial carcinoma:1||Upper urinary tract cancer:1||Urachal cancer:1||Uropathogen:1||Urothelial:1||Urothelial cancer:1||Ursodiol:1||VEGFR2 inhibitor:1||Vascular endothelial growth factor:1||Venoocclusive disease:1||WHO classification:1||Wholeexome sequencing:1||Wholetranscriptome sequencing:1||XBP1:1||XELIRI/FOLFIRI chemotherapy:1||advanced gastric cancer:1||advanced urothelial carcinoma:1||amplification:1||and Tumor burden:1||and margetuximab plus pembrolizumab:1||anemia:1||angiogenesis:1||antiangiogenesis:1||aspartate transaminase/alanine transaminase (De Ritis) ratio:1||atezolizumab:1||best supportive care:1||bevacizumab:1||biliary tract cancer:1||biomarkers:1||bone metastases:1||bone metastasis:1||brain metastases:1||cancer:1||carcinoma:1||castrate&:1||cellfree DNA (cfDNA):1||central nervous system:1||claudin 18.2:1||clinical trial:1||clinical trials:1||clonogenic assay:1||coactivation:1||collagen induced arthritis:1||colon cancer:1||colorectal cancer:1||colorectal cancer (CRC):1||colorectal carcinoma:1||computational biology:1||concurrent chemoradiotherapy:1||consolidation therapy:1||crizotinib:1||cutoff points:1||dRecurrence:1||dacomitinib:1||digital sequencing:1||durvalumab:1||elderly:1||enfortumab vedotin:1||epidermal growth factor receptor mutant nonsmallcell lung cancer:1||epithelial–mesenchymal transition (EMT):1||erdafitinib:1||etoposide:1||extensive:1||extranodal NK/T cell lymphoma:1||fluorescence:1||fusion:1||gastric carcinoma:1||gastroenteropancreatic neuroendocrine carcinoma (GEPNEC)s:1||gastrointestinal cancer:1||gastrointestinal malignancies:1||gastrointestinal tract:1||gene expression:1||gene signature:1||genetic diagnosis:1||genomewide association:1||genomic:1||genomic alterations:1||genomic test:1||head and neck squamous cell carcinoma (HNSCC):1||healthrelated quality of life:1||hepatocyte growth factor:1||highthroughput drug screening:1||hypoxia:1||immune check point inhibitor:1||immune checkpoint blockade:1||immune checkpoint inhibitor:1||immune checkpoint inhibitor (ICI):1||immune infiltrates:1||immunohistochemistry:1||immunology:1||intrinsic resistance:1||irinotecan:1||kidney:1||kidney neoplasms:1||lenvatinib plus pembrolizumab:1||leptomeningeal disease:1||leptomeningeal metastases:1||leukocyte count:1||liquid biopsy:1||low skeletal muscle mass:1||lymph node:1||mTOR:1||mTORC1/2:1||margetuximab plus pembrolizumab:1||mesenchymal:1||metastatic cancers:1||metastatic urothelial cancer:1||mismatch repair deficiency (dMMR):1||molecular features:1||molecular profiling:1||mortality:1||myosteatosis:1||natural history:1||neoplasm metastasis:1||nephrectomy:1||neuropathy:1||nextgeneration sequencing (NGS):1||noninferiority:1||nonsmall cell lung cancer:1||nonsmallcell lun:1||nonsmallcell lung:1||nonsmallcell lung cancer:1||oesophageal cancer:1||omics:1||oncology:1||oral paclitaxel:1||oxaliplatin:1||pSTAT3:1||paclitaxel:1||pancreatic adenocarc:1||pancreatic cancer:1||panel sequencing:1||pathologic differentiation:1||pathology:1||pathway:1||patientderived cells:1||patientderived tumor cell:1||patientderived tumor cells:1||pazopanib:1||pemetrexed:1||peritoneal mesothelioma:1||pharmacodynamics:1||pharmacokinetics:1||phase I:1||platelet count:1||platinum:1||platinum ineligibility:1||platinumbased chemotherapy:1||precision:1||prediction model:1||primary tumor site:1||prognostic factor:1||programed death protein&:1||programmed deathligand 1 (PDL1):1||progression:1||progression free survival:1||propensityscore matching analysis:1||proteintyrosine kinases:1||radical cystectomy:1||radiosensitivity:1||radium&:1||realworld:1||recurrence:1||regorafenib:1||relapse:1||renal cell:1||resistant prostate cancer:1||responsiveness:1||rheumatoid arthritis:1||scoring model:1||selumetinib:1||sequencing:1||simvastatin:1||singlecell RNA sequencing:1||singlenucleotide variants:1||sirolimus:1||solid cancer:1||sorafenib:1||squamous esophageal cancer:1||stage smallcell lung cancer:1||subtypes:1||survival outcomes:1||targeted alpha therapy:1||targeted therapy:1||therapy:1||threeweek schedule:1||tislelizumab:1||transcriptomics:1||tremelimumab:1||tumor:1||tumor biomarkers:1||tumor heterogeneity:1||tumor microenvironment:1||tumor mutational burden:1||tumor purity:1||twodrug combination:1||tyrosine kinase inhibitor:1||tyrosine kinase inhibitors:1||vitamin:1||vitamin C:1||young:1||zolbetuximab:1||약물 치료:1||전립선암:1||전이:1||치료지침:1||1:1||18FFDG PET/CT:1||223:1||30min infusion:1||5fluorouracil:1||AKT:1||ARON1 study:1||ARON2 study:1||ARON2(EV) study:1||ASCL1:1||ATM:1||AZD5363:1||Abiraterone acetate:1||Actinotignum schaalii:1||Adenocarcinoma of ampulla of Vater:1||Adjuvant CCRT:1||Adjuvant chemoradiotherapy:1||Adrenal cortical carcinoma:1||Advanced gastric cancer (AGC):1||Advanced hepatocellular carcinoma:1||Advanced urothelial carcinoma:1||Aflibercept:1||Ampliseq:1||And vascular endothelial growth factor receptor 2 (VEGFR2):1||Angiogenesis:1||AntiEGFR:1||AntiPD1 antibodies:1||Antiangiogenic agent:1||Antibiotics:1||Antibodies, monoclonal, humanized:1||Antineoplastic agents:1||Anti–PDL1:1||Asia:1||AsiaPacific:1||Asian:1||Asian patient:1||Asian patients:1||Asian population:1||Awareness and willi:1||Axitinib:1||BEZ235:1||Bevacizumab:1||Beyond first progression:1||Biliary tract cancer:1||Brain metastasis:1||Brief pain inventory:1||CAPOX:1||CD274:1||CDK4/6 inhibitor:1||CPT11:1||Cancer clinical trial:1||Cancer pain:1||Capecitab:1||Carbonic anhydrase IX:1||Carcinoma, Esophageal neoplasm:1||Castrateresistant prostate cancer:1||Castrationnaïve prostate cancer:1||Cellfree DNA (cfDNA):1||Cerebrospinal fluid (CSF):1||Chemoradiation:1||Chemoradiotherapy:1||Choriocarcinoma:1||Chromogranin A:1||Circulating tumor cell:1||Circulating tumor cells (CTCs):1||Cisplatin Ineligible:1||Cisplatinbased combination chemotherapy:1||Clearcell carcinoma:1||Clinical trials:1||Colonic neoplasms:1||Colorectal cancer (CRC):1||Competing risk analysis:1||Concomitant drug score:1||Concomitant medication:1||Concurrent chemoradiotherapy:1||Cortico:1||Corticosteroids:1||Cox regression:1||Cushing's syndrome:1||Cyclooxygenase2:1||DHP107:1||DLL4:1||DNA:1||DNA target sequencing:1||DP:1||Delphi consensus:1||Dexamethasone:1||Digital sequencing:1||Distal cholangiocarcinoma:1||Dual blockade:1||EGFR T790M:1||EGFR tyrosine kinase inhibitor:1||ERBB2:1||Early death:1||Elderly:1||Epacadostat:1||Epirubicin:1||ErbB receptors:1||ErbB2:1||ErbB2 receptor:1||Erdafitinib:1||Esophageal neoplasms:1||Ethnic groups:1||Exon 20 insertion:1||FGFR2:1||FGFR2 amplification:1||FGFR2amplified:1||FLT3 amplification:1||FOLFIRI:1||FOLFOX4:1||Fentanyl:1||Fibroblast growth factor inhibitor:1||First line:1||Firstline:1||Firstline palliative chemotherapy:1||Fluoropyrimidine:1||Fluorouracil (FU):1||Fusion:1||GEPNEC:1||Gallbladder neoplasms:1||Gastrectomy:1||Gastric:1||Gastric adenocarcinoma:1||Gastroenteropancreatic neuroendocrine tumor:1||Gastrooesophageal junction cancer:1||Gastroenteropancreatic neuroendocrine carcinoma:1||Gefitinib:1||Gemcitabine failure:1||Gender differences:1||Gene mutations:1||Genitourinary Cancer:1||Genome:1||Genomic analysis:1||Genomic test:1||Germ cell tumor:1||Glomerular filtration rate:1||Glycolysis:1||Glycopeptide:1||Glycoprotein:1||Guardant360:1||Guideline:1||HRD:1||Hematogenous:1||Hematology/Oncology:1||Hematopoietic stem cell transplantation:1||Hemodialysis:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE